Chin Med J (Engl):舌下免疫治疗药片能够减轻成年人过敏性鼻炎症状

2018-11-13 AlexYang MedSci原创

舌下免疫治疗(SLIT)在屋尘螨诱导的过敏性鼻炎中具有很好的治疗效果。然而,成年人过敏性鼻炎中,SLIT药片对其的治疗效果还未见报道。最近,有研究人员通过元分析阐释了SLIT对过敏性鼻炎的差异化治疗效果。研究总共包括了7个相关的研究,总共鉴定了2723名患者。所有的研究均为随机对照研究(RCT),且上述7个研究均在成年人中进行。在这7篇文献中,有5个研究对患者进行了SLIT药片治疗,并且符合鼻炎总

舌下免疫治疗(SLIT)在屋尘螨诱导的过敏性鼻炎中具有很好的治疗效果。然而,成年人过敏性鼻炎中,SLIT药片对其的治疗效果还未见报道。最近,有研究人员通过元分析阐释了SLIT对过敏性鼻炎的差异化治疗效果。

研究总共包括了7个相关的研究,总共鉴定了2723名患者。所有的研究均为随机对照研究(RCT),且上述7个研究均在成年人中进行。在这7篇文献中,有5个研究对患者进行了SLIT药片治疗,并且符合鼻炎总症状评分(RTSS)元分析,总共有1490名患者。总的来讲,与安慰剂组对比,RTSS在SLIT药物治疗组中具有显著的降低(标准均差=-0.33,95%置信区间 [-0.54, -0.13], P < 0.01)。另外,在SLIT治疗患者和安慰剂治疗患者之间,lgE水平没有明显的差异。

最后,研究人员指出,SLIT药片能够有效的减轻成年人过敏性鼻炎症状。尽管如此,目前的证据由于样本大小和研究的异质性受到应用限制,因此,还需要进一步的研究。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081504, encodeId=b46d2081504f8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Feb 04 19:53:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785538, encodeId=c26c1e8553834, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Mar 08 04:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047042, encodeId=3750204e042dc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Feb 03 21:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353140, encodeId=5fa23531400a, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Nov 20 10:00:30 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609308, encodeId=d3741609308b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Nov 15 04:53:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-02-04 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081504, encodeId=b46d2081504f8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Feb 04 19:53:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785538, encodeId=c26c1e8553834, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Mar 08 04:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047042, encodeId=3750204e042dc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Feb 03 21:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353140, encodeId=5fa23531400a, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Nov 20 10:00:30 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609308, encodeId=d3741609308b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Nov 15 04:53:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-03-08 haouestc
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081504, encodeId=b46d2081504f8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Feb 04 19:53:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785538, encodeId=c26c1e8553834, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Mar 08 04:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047042, encodeId=3750204e042dc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Feb 03 21:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353140, encodeId=5fa23531400a, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Nov 20 10:00:30 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609308, encodeId=d3741609308b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Nov 15 04:53:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081504, encodeId=b46d2081504f8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Feb 04 19:53:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785538, encodeId=c26c1e8553834, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Mar 08 04:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047042, encodeId=3750204e042dc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Feb 03 21:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353140, encodeId=5fa23531400a, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Nov 20 10:00:30 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609308, encodeId=d3741609308b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Nov 15 04:53:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-11-20 zwjnj2

    好好学习天天学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2081504, encodeId=b46d2081504f8, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Mon Feb 04 19:53:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785538, encodeId=c26c1e8553834, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Mar 08 04:53:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047042, encodeId=3750204e042dc, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Feb 03 21:53:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353140, encodeId=5fa23531400a, content=好好学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Tue Nov 20 10:00:30 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609308, encodeId=d3741609308b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Nov 15 04:53:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-11-15 hb2008ye

相关资讯

BJC:出现免疫相关不良反应的肿瘤患者存在免疫失调

高达40%的接受免疫检查点抑制剂治疗的肿瘤患者临床上会出现显着的免疫相关不良事件(irAE)。宿主免疫状态和功能在诱发患者免疫相关不良事件中的作用仍然未知。BJC近期发表了一篇文章研究这一问题。

PNAS:中和活性氮分子增强癌症免疫治疗

利用T细胞攻击体内癌细胞(免疫疗法)虽然给部分化疗患者带来了希望,然而,一些患者经过一轮又一轮治疗仍然效果甚微。尽管免疫疗法前景看好,它仍然只对少数患者有利,这是该领域需要改进新方法的驱动力。

NEJM:免疫治疗在晚期三阴乳腺癌III期临床试验中成功!中位总生存期提高61.3%

《新英格兰医学杂志》便再次传来捷报。PD-L1抑制剂首次在晚期三阴乳腺癌临床Ⅲ期试验中取得重大胜利!该试验是由伦敦玛丽女王大学Peter Schmid教授领导的团队完成的。他们将免疫检查点抑制剂Atezolizumab与化疗药物白蛋白结合型紫杉醇(nab-paclitaxel)联用,与单独使用白蛋白结合型紫杉醇相比,PD-L1阳性的晚期三阴乳腺癌患者中位总生存期提升了近10个月,达到25个月,

Front Immunol:中科院广州生物院等在艾滋病疫苗研究取得新进展

中国科学院广州生物医药与健康研究院等单位联合在艾滋病预防性疫苗研究中取得新进展,相关成果以“Immune protection of SIV challenge by PD-1 blockade during vaccination in rhesus monkeys”为题发表在国际免疫学术期刊Frontiers in Immunology。

2018 ESMO:沈琳教授团队专访:突破神经内分泌肿瘤疗效瓶颈,免疫治疗任重而道远

近日,2018 ESMO大会在德国慕尼黑隆重召开。在本次ESMO大会上,由北京大学肿瘤医院沈琳教授牵头的JS001治疗晚期神经内分泌肿瘤的IB期研究的结果得以口头报告公布。JS001是我国君实生物自主研发具有全球知识产权的重组人源化PD-1单抗,前期临床研究表明JS001在多个瘤种中均具有一定疗效。特别采访到沈琳教授及其团队的李洁教授和张盼盼博士,共同解读与探讨这项研究的结果。

CLIN CANCER RES:利用PET检测CD8+T细胞密度

利用PET 对CD8 + T细胞进行无创和定量评估可以用于评估免疫治疗反应。CLIN CANCER RES近期发表了一篇文章,应用标记有64 Cu 的抗CD8 cys-双抗体来评估正常组织和并不组织的PET成像敏感性。